Michael P. Sanderson

3.5k total citations · 2 hit papers
42 papers, 2.4k citations indexed

About

Michael P. Sanderson is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Michael P. Sanderson has authored 42 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Oncology and 7 papers in Immunology. Recurrent topics in Michael P. Sanderson's work include Peptidase Inhibition and Analysis (10 papers), Ubiquitin and proteasome pathways (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Michael P. Sanderson is often cited by papers focused on Peptidase Inhibition and Analysis (10 papers), Ubiquitin and proteasome pathways (10 papers) and Multiple Myeloma Research and Treatments (6 papers). Michael P. Sanderson collaborates with scholars based in Germany, United States and Austria. Michael P. Sanderson's co-authors include Peter Altevogt, Sascha Keller, Alexander Stoeck, Andreas Zoephel, Eric Haaksma, Flavio Solca, Frank Himmelsbach, Christian Klein, Oliver Kraemer and Guenther R. Adolf and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Cancer Research.

In The Last Decade

Michael P. Sanderson

41 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomes: From biogenesis and secretion to biological function

2006 713 citations Sascha Keller, Michael P. Sanderson et al. profile →
Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker

2012 684 citations Flavio Solca, Andreas Zoephel et al. Journal of Pharmacology and Experimental Therapeutics profile →

Peers

Michael P. Sanderson

ONCOL

PRM

IMMUN

Leticia Oliveira‐Ferrer Germany

Dorina Belotti Italy

Frank Hilberg Austria

Pornchai O‐charoenrat Thailand

R. Daniel Bonfil United States

Rachel Tsan United States

Roman Nawroth Germany

Alicia Viloria‐Petit Canada

Amir Moghaddam United Kingdom

Todd Hembrough United States

Leticia Oliveira‐Ferrer Germany

Michael P. Sanderson

1.4k ×0.9

712 ×0.9

ONCOL

645 ×1.1

362 ×0.7

PRM

458 ×1.6

IMMUN

Citations per year, relative to Michael P. Sanderson Michael P. Sanderson (= 1×) peers Leticia Oliveira‐Ferrer

Countries citing papers authored by Michael P. Sanderson

Since Specialization

Citations

This map shows the geographic impact of Michael P. Sanderson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Sanderson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Sanderson more than expected).

Fields of papers citing papers by Michael P. Sanderson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Sanderson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Sanderson. The network helps show where Michael P. Sanderson may publish in the future.

Co-authorship network of co-authors of Michael P. Sanderson

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Sanderson. A scholar is included among the top collaborators of Michael P. Sanderson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Sanderson. Michael P. Sanderson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xie, Xuemei, Jangsoon Lee, Ganiraju C. Manyam, et al.. (2025). LMP7-Specific Inhibitor M3258 Modulates the Tumor Microenvironment of Triple-Negative Breast Cancer and Inflammatory Breast Cancer. Cancers. 17(11). 1887–1887. 1 indexed citations

Stumpp, Michael T., Vladimir Kirkin, Michael P. Sanderson, Keith M. Dawson, & Philippe Legenne. (2025). A Decade of Clinical Experience with DARPins in Oncology and Virology: A Systematic Review. medRxiv. 2 indexed citations

Jongen‐Lavrencic, Mojca, Thomas Pabst, Pierre Bories, et al.. (2024). MP0533 (CD33 x CD123 x CD70 x CD3), a Tetra-Specific CD3-Engaging Darpin for the Treatment of Patients with Relapsed/Refractory AML or MDS/AML: Results of an Ongoing Phase 1/2a Study. Blood. 144(Supplement 1). 2881–2881. 4 indexed citations

Esdar, Christina, Manja Friese‐Hamim, Sofia Stinchi, et al.. (2022). Translational PK/PD Modeling of Tumor Growth Inhibition and Target Inhibition to Support Dose Range Selection of the LMP7 Inhibitor M3258 in Relapsed/Refractory Multiple Myeloma. Journal of Pharmacology and Experimental Therapeutics. 384(1). 163–172. 5 indexed citations

Sanderson, Michael P., Manja Friese‐Hamim, Michael Busch, et al.. (2021). M3258 Is a Selective Inhibitor of the Immunoproteasome Subunit LMP7 (β5i) Delivering Efficacy in Multiple Myeloma Models. Molecular Cancer Therapeutics. 20(8). 1378–1387. 30 indexed citations

Bogatyrova, Olga, Johanna Sofia Margareta Mattsson, Edith Ross, et al.. (2021). FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response. European Journal of Cancer. 151. 136–149. 32 indexed citations

Viteri, Santiago, Christopher Stroh, Nina Linde, et al.. (2020). SHP2 Inhibition Influences Therapeutic Response to Tepotinib in Tumors with MET Alterations. iScience. 23(12). 101832–101832. 8 indexed citations

Esdar, Christina, et al.. (2019). Abstract 4853: M6123 is an ADCC-enhanced and selective monovalent antagonist of FGFR1 showing antitumor activity in preclinical lung cancer models. Cancer Research. 79(13_Supplement). 4853–4853. 2 indexed citations

Aleksic, Tamara, Nicki Gray, Xiaoning Wu, et al.. (2018). Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage. Cancer Research. 78(13). 3497–3509. 50 indexed citations

10.

Sanderson, Michael P., Marco H. Hofmann, Pilar Garin‐Chesa, et al.. (2017). The IGF1R/INSR Inhibitor BI 885578 Selectively Inhibits Growth of IGF2-Overexpressing Colorectal Cancer Tumors and Potentiates the Efficacy of Anti-VEGF Therapy. Molecular Cancer Therapeutics. 16(10). 2223–2233. 22 indexed citations

11.

Schaaf, Otmar, Marco H. Hofmann, Michael P. Sanderson, et al.. (2017). An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor. Cancer Chemotherapy and Pharmacology. 79(3). 545–558. 6 indexed citations

12.

Schaaf, Otmar, Marco H. Hofmann, Michael P. Sanderson, et al.. (2016). A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques. Cancer Chemotherapy and Pharmacology. 77(6). 1303–1314. 5 indexed citations

13.

Sanderson, Michael P., Joshua F. Apgar, Pilar Garin‐Chesa, et al.. (2015). BI 885578, a Novel IGF1R/INSR Tyrosine Kinase Inhibitor with Pharmacokinetic Properties That Dissociate Antitumor Efficacy and Perturbation of Glucose Homeostasis. Molecular Cancer Therapeutics. 14(12). 2762–2772. 16 indexed citations

14.

Sanderson, Michael P.. (2015). Evolving the Firm: Meeting the Needs of a 21st Century Economy and Workforce. ITE journal. 85(1). 1 indexed citations

15.

Solca, Flavio, Andreas Zoephel, Gerd Bader, et al.. (2012). Target Binding Properties and Cellular Activity of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker. Journal of Pharmacology and Experimental Therapeutics. 343(2). 342–350. 684 indexed citations breakdown →

16.

Sanderson, Michael P., et al.. (2009). Syk: A Novel Target for Treatment of Inflammation in Lung Disease. Inflammation & Allergy - Drug Targets. 8(2). 87–95. 13 indexed citations

17.

Sanderson, Michael P., et al.. (2009). Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcεRI-activated RBL-2H3 basophilic cells. Cellular Immunology. 262(1). 28–34. 18 indexed citations

18.

Sanderson, Michael P., Sascha Keller, Ángel Alonso, et al.. (2007). Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease‐dependent ectodomain shedding and exosome secretion. Journal of Cellular Biochemistry. 103(6). 1783–1797. 97 indexed citations

19.

Sanderson, Michael P., Catherine A. Abbott, Hiroko Tada, et al.. (2006). Hydrogen peroxide and endothelin‐1 are novel activators of betacellulin ectodomain shedding. Journal of Cellular Biochemistry. 99(2). 609–623. 20 indexed citations

20.

Sanderson, Michael P., Peter J. Dempsey, & Andrew Dunbar. (2006). Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors. Growth Factors. 24(2). 121–136. 109 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact